Abstract
Finding novel compounds as starting points for optimization is a major challenge in drug discovery research. Fragment-based methods have emerged in the past ten years as an effective way to sample chemical diversity with a limited number of low molecular weight compounds. The structures of the fragments(s) binding to the protein can then be used to design new compounds with increased affinity, specificity and novelty. This article describes the Vernalis approach to fragment based drug discovery, called SeeDs (Structural exploitation of experimental Drug startpoints). The approach includes the design of a fragment library, identification of fragments that bind competitively to a target by ligand-based NMR techniques and protein crystal structures to characterize binding. Fragments that bind are then evolved to hits, either by growing the fragment or by combining structural features from a number of compounds. The process is illustrated with examples from recent medicinal chemistry programmes to discover compounds against the oncology targets Hsp90 and PDK1. In addition, we summarise our experience with using molecular docking calculations to predict fragment binding and anecdotes on the selectivity and binding modes for fragments seen against a range of targets.
Keywords: Structure-based drug discovery, fragment-based drug discovery, drug design, NMR spectroscopy, Hsp90, PDK1
Current Topics in Medicinal Chemistry
Title: The SeeDs Approach: Integrating Fragments into Drug Discovery
Volume: 7 Issue: 16
Author(s): Roderick E. Hubbard, Ben Davis, Ijen Chen and Martin J. Drysdale
Affiliation:
Keywords: Structure-based drug discovery, fragment-based drug discovery, drug design, NMR spectroscopy, Hsp90, PDK1
Abstract: Finding novel compounds as starting points for optimization is a major challenge in drug discovery research. Fragment-based methods have emerged in the past ten years as an effective way to sample chemical diversity with a limited number of low molecular weight compounds. The structures of the fragments(s) binding to the protein can then be used to design new compounds with increased affinity, specificity and novelty. This article describes the Vernalis approach to fragment based drug discovery, called SeeDs (Structural exploitation of experimental Drug startpoints). The approach includes the design of a fragment library, identification of fragments that bind competitively to a target by ligand-based NMR techniques and protein crystal structures to characterize binding. Fragments that bind are then evolved to hits, either by growing the fragment or by combining structural features from a number of compounds. The process is illustrated with examples from recent medicinal chemistry programmes to discover compounds against the oncology targets Hsp90 and PDK1. In addition, we summarise our experience with using molecular docking calculations to predict fragment binding and anecdotes on the selectivity and binding modes for fragments seen against a range of targets.
Export Options
About this article
Cite this article as:
Hubbard E. Roderick, Davis Ben, Chen Ijen and Drysdale J. Martin, The SeeDs Approach: Integrating Fragments into Drug Discovery, Current Topics in Medicinal Chemistry 2007; 7 (16) . https://dx.doi.org/10.2174/156802607782341109
DOI https://dx.doi.org/10.2174/156802607782341109 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antagonists of IAP Proteins: Novel Anti-Tumor Agents
Current Medicinal Chemistry IVGA3D: De Novo Ligand Design Using a Variable Sized Tree Representation
Protein & Peptide Letters Receptor Guided 3D-QSAR Analysis of Thieno[2,3-b]Pyridine-5- Carbonitrile Inhibitors of Protein Kinase C Theta (PKC-θ )
Combinatorial Chemistry & High Throughput Screening Variable Selection in QSAR Models for Drug Design
Current Computer-Aided Drug Design Protein Phosphatase Inhibition: Structure Based Design. Towards New Therapeutic Agents
Current Pharmaceutical Design In Silico Technology for Identification of Potentially Toxic Compounds in Drug Discovery
Current Computer-Aided Drug Design The Mouse Model of Chlamydia Genital Tract Infection: A Review of Infection, Disease, Immunity and Vaccine Development
Current Molecular Medicine New Patentable Use of an Old Neuroleptic Compound Thioridazine to Combat Tuberculosis: A Gene Regulation Perspective
Recent Patents on Anti-Infective Drug Discovery Thienopyridone Antibacterials. Part IV[1]. Synthesis of Some N(7)- Heteroaryl-4-oxothieno[2,3-b]pyridine-5-carboxylic Acids and Esters
Letters in Organic Chemistry MTDL Design Strategy in the Context of Alzheimers Disease: From Lipocrine to Memoquin and Beyond
Current Pharmaceutical Design Editorial from Guest Editor [Hot topic: The Optimal Care of the Lung in the Critically Ill (Guest Editor: Ross Freebairn)]
Current Respiratory Medicine Reviews A Guide to Treatment of Sarcoidosis
Current Drug Therapy Synthesis and Biological Evaluation of 1, 3-Dihydroxyxanthone Mannich Base Derivatives as Potential Antitumor Agents
Letters in Drug Design & Discovery Implications of Photophysical and Physicochemical Factors on Successful Application of Photodynamic Therapy
Current Pharmaceutical Design The Role of Unbound Drug in Pharmacokinetics/Pharmacodynamics and in Therapy
Current Pharmaceutical Design Inhibitors of the Immunoproteasome: Current Status and Future Directions
Current Pharmaceutical Design Multifunctional Radiolabeled Nanoparticles for Targeted Therapy
Current Medicinal Chemistry Phenylpyazoleanilides as a Potent Inhibitor of IL-15 Dependent T Cell Proliferation. Part 1: A New Class of Orally Available Immunomodulators
Letters in Drug Design & Discovery Competition Between Tumor and Mononuclear Phagocyte System Causing the Low Tumor Distribution of Nanoparticles and Strategies to Improve Tumor Accumulation
Current Drug Delivery Monosubstituted Coumarins Inhibit Epinephrine-induced Platelet Aggregation
Cardiovascular & Hematological Agents in Medicinal Chemistry